Andrea Ferrari
A5100686232- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Tumors and Oncological Cases
- Vascular Tumors and Angiosarcomas
- Neuroblastoma Research and Treatments
- Cardiac tumors and thrombi
- Family Support in Illness
- Testicular diseases and treatments
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Bone Tumor Diagnosis and Treatments
- CAR-T cell therapy research
- Surgical site infection prevention
- Soft tissue tumor case studies
- Congenital Diaphragmatic Hernia Studies
- Palliative Care and End-of-Life Issues
- Adolescent and Pediatric Healthcare
- Ethics and Legal Issues in Pediatric Healthcare
- Renal and related cancers
- Glioma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cutaneous Melanoma Detection and Management
- Neurofibromatosis and Schwannoma Cases
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
Fondazione IRCCS Istituto Nazionale dei Tumori
2016-2025
Healthwise
2024-2025
Creighton University
2025
Phoenix (United States)
2025
University of Arizona
2025
University of Milan
2012-2025
University of Cambridge
2018-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2024
European Organization for Nuclear Research
2011-2024
Policlinico San Matteo Fondazione
2024
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
Purpose To compare clinical features and outcomes of adults children reported to have rhabdomyosarcoma. Patients Methods We analyzed data from 1,071 (age > 19 years) 1,529 ≤ in the public-access Surveillance, Epidemiology End Results database as having rhabdomyosarcoma, diagnosed 1973 2005. Survival estimates were determined using survival time with end point being death any cause. Adults rhabdomyosarcoma had significantly worse outcome than (5-year overall rates, 27% ± 1.4% 61% 1.4%,...
The authors explored the prognostic factors and clinical outcomes of patients who had malignant peripheral nerve sheath tumors (MPNST) with without neurofibromatosis type 1 (NF-1).Two hundred five localized MPNST underwent surgery at Istituto Nazionale per lo Studio e la Cura dei Tumori (Milan, Italy) over 25 years were reviewed. Forty-six concomitant NF-1 syndrome, 159 did not. Local recurrence, distant metastases, survival rates studied.One thirty presented primary disease, 75 locally...
Abstract BACKGROUND The optimal treatment strategy for synovial sarcoma (SS) is subject to debate, and different strategies have been used pediatric adult patients. current retrospective analysis examined a large group of patients all ages who were treated at single institution over 30‐year period. METHODS study included 271 ranged in age from 5 years 87 years; 255 had localized disease, which was macroscopically resected 215 cases deemed unresectable diagnosis 40 cases. Chemotherapy...
To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath tumors (MPNSTs) to identify risk factors associated outcome.A total 167 untreated eligible patients enrolled onto Italian German studies between 1975 1998 entered this analysis. Seventeen percent had neurofibromatosis type 1 (NF1). Chemotherapy was administered 74% patients; 38% patients.With a median follow-up 7 years, 5-year overall survival (OS) progression-free (PFS) were 51% 37%,...
Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies that occur throughout the lifespan. The impact age on disease features and outcome is unclear.We analyzed clinical all STS cases registered between 1973 2006 in SEER database.There were 48,012 met selection criteria. Individuals less than 20 years represented 5.6%, with rhabdomyosarcoma being most common subtype. In adults, types Kaposi sarcoma, fibrohistiocytic tumors, leiomyosarcoma. Rhabdomyosarcoma was only...
Synovial sarcoma (SS) is a typical soft tissue subtype crosswise between the pediatric and adult age groups. Less satisfactory overall outcome has been recorded in series.This study compares clinical features outcomes of SS across different groups, by analyzing 1268 cases, 213 children/adolescents (<or=18 years) 1055 adults, registered Surveillance, Epidemiology, End Results (SEER) 17 database from 1983 to 2005. Cancer-specific survival estimates were compared with univariate multivariate...